Telaprevir for previously treated chronic HCV infection

Area of Science:

• Hepatology and Viral Gastroenterology
• Clinical Trial Design and Analysis
• Pharmacotherapy for Viral Infections

Background:

• Patients with genotype 1 hepatitis C virus (HCV) often have poor outcomes with retreatment after initial peginterferon alfa and ribavirin therapy failure.
• Identifying effective retreatment strategies is crucial for improving sustained virologic response (SVR) rates in this patient population.

Purpose of the Study:

• To evaluate the efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin as a retreatment option for genotype 1 HCV patients.
• To compare SVR rates between different telaprevir-based regimens and a control group receiving standard therapy.

Main Methods:

• Randomized trial assigning genotype 1 HCV patients with prior treatment failure to four groups: T12PR24, T24PR48, T24P24 (telaprevir combinations), or PR48 (control).
• Primary endpoint: sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks post-treatment.
• Telaprevir dosages varied in duration (12 or 24 weeks), combined with 24 or 48 weeks of peginterferon alfa-2a and ribavirin.

Main Results:

• SVR rates were significantly higher in telaprevir groups (51-53%) compared to the control group (14%) (P<0.001 for T12PR24 and T24PR48; P=0.02 for T24P24).
• Higher response rates observed in patients with prior relapses versus non-responders.
• Rash was a common adverse event (51%), with severe rash in 5%; drug discontinuation due to adverse events was higher in telaprevir groups (15% vs. 4%).

Conclusions:

• Telaprevir combined with peginterferon alfa-2a and ribavirin is a more effective retreatment strategy than peginterferon alfa-2a and ribavirin alone for genotype 1 HCV patients with prior treatment failure.
• The study provides evidence supporting the use of direct-acting antivirals like telaprevir in retreatment regimens for difficult-to-treat HCV populations.